Author:
Bekaii-Saab Tanios S,Ou Fang-Shu,Ahn Daniel H,Boland Patrick M,Ciombor Kristen K,Heying Erica N,Dockter Travis J,Jacobs Nisha L,Pasche Boris C,Cleary James M,Meyers Jeffrey P,Desnoyers Rodwige J,McCune Jeannine S,Pedersen Katrina,Barzi Afsaneh,Chiorean E Gabriela,Sloan Jeffrey,Lacouture Mario E,Lenz Heinz-Josef,Grothey Axel
Reference21 articles.
1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;Ca Cancer J Clin,2018
2. Regorafenib (BAY 73–4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity;Wilhelm;Int J Cancer,2011
3. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial;Grothey;Lancet,2013
4. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial;Li;Lancet Oncol,2015
5. Time profile of adverse events (AEs) from regorafenib (REG) treatment for metastatic colorectal cancer (mCRC) in the phase III CORRECT study;Grothey;Proc Am Sol Clin Oncol,2013
Cited by
195 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献